One hypothesis for those conflicting results is that AR activation in EGFRvIII-expressing cells is partly achieved by AR phosphorylation at additional residues, by alternative signaling pathways, as known from prostate cancer [43]. This evidence concerns the gene AR and Familial prostate cancer.